Monitoring of bone marrow cell homing into the infarcted human myocardium
Monitoring of bone marrow cell homing into the infarcted human myocardium
复制标题
DOI：
10.1161/01.cir.0000163546.27639.aa
复制
发表时间：
2005-05-03
期刊：
影响因子：
37.8
通讯作者：
Drexler, H
中科院分区：
文献类型：
--
作者：
Hofmann, M;Wollert, KC;Drexler, H
自体骨髓细胞（BMCs）冠状动脉内移植促进急性心肌梗死患者左心室收缩功能的恢复。虽然这种影响的机制仍有待建立，归巢的BMC到梗死myocardium可能是一个关键的早期events.Methods和Results-We确定BMC的生物分布后，治疗应用在第一个ST段抬高心肌梗死患者谁经历了支架植入术的梗死相关动脉。用100 MBq 2-[F-18]-氟-2-脱氧-D-葡萄糖（F-18-FDG）放射性标记未选择的BMC，并将其输注到梗死相关冠状动脉（冠状动脉内; n = 3例患者）或通过肘前静脉注射（静脉内; n = 3例患者）。在另外3名患者中，从自体骨髓单个核细胞中免疫磁性富集CD 34阳性（CD 34（+））细胞，用F-18-FDG标记，并冠状动脉内输注。在支架植入后5至10天进行细胞移植。超过99%的输注总放射性与细胞结合。所有制备物中的有核细胞活力相当，范围为92%至96%。在细胞转移后50至75分钟，所有患者都接受了3D PET成像。冠状动脉内转移后，在梗死心肌中检测到1.3%至2.6%的F-18-FDG-标记的BMCs;剩余的活性主要在肝脏和脾脏中发现。静脉内转移后，在梗死心肌中仅检测到背景活性。冠状动脉内转移F-18-FDG标记的富含CD 34的细胞后，在梗死心肌中检测到总活性的14%至39%。未经选择的骨髓基质细胞移植在梗死中心和边界区;归巢的CD 34-富集细胞更明显的边界zone. Conclusions-F-18-FDG标记和三维PET成像可用于监测心肌归巢和生物分布的骨髓基质细胞治疗应用后，在患者。
Background-Intracoronary transfer of autologous bone marrow cells (BMCs) promotes recovery of left ventricular systolic function in patients with acute myocardial infarction. Although the mechanisms of this effect remain to be established, homing of BMCs into the infarcted myocardium is probably a critical early event.Methods and Results-We determined BMC biodistribution after therapeutic application in patients with a first ST-segment-elevation myocardial infarction who had undergone stenting of the infarct-related artery. Unselected BMCs were radiolabeled with 100 MBq2-[F-18]-fluoro-2-deoxy-D-glucose (F-18-FDG) and infused into the infarct-related coronary artery (intracoronary; n = 3 patients) or injected via an antecubital vein (intravenous; n = 3 patients). In 3 additional patients, CD34-positive (CD34(+)) cells were immunomagnetically enriched from unselected BMCs, labeled with F-18-FDG, and infused intracoronarily. Cell transfer was performed 5 to 10 days after stenting. More than 99% of the infused total radioactivity was cell bound. Nucleated cell viability, comparable in all preparations, ranged from 92% to 96%. Fifty to 75 minutes after cell transfer, all patients underwent 3D PET imaging. After intracoronary transfer, 1.3% to 2.6% of F-18-FDG-labeled unselected BMCs were detected in the infarcted myocardium; the remaining activity was found primarily in liver and spleen. After intravenous transfer, only background activity was detected in the infarcted myocardium. After intracoronary transfer of F-18-FDG-labeled CD34-enriched cells, 14% to 39% of the total activity was detected in the infarcted myocardium. Unselected BMCs engrafted in the infarct center and border zone; homing of CD34-enriched cells was more pronounced in the border zone.Conclusions-F-18-FDG labeling and 3D PET imaging can be used to monitor myocardial homing and biodistribution of BMCs after therapeutic application in patients.